Electromed Reports Record Q2 2026 Revenue and Profitability

Electromed ( (ELMD) ) just unveiled an update.

Electromed, Inc., a medical device maker specializing in airway clearance systems such as its SmartVest® product for patients with chronic pulmonary conditions, reported record financial results for its fiscal 2026 second quarter, covering the three months ended December 31, 2025. The company, which targets the large bronchiectasis market primarily through its homecare channel and a growing direct salesforce, continues to operate with no debt and solid liquidity.

In Q2 FY 2026, net revenue rose 16.3% year over year to a record $18.9 million, driven by an 18.4% increase in direct homecare revenue to $17.3 million as more sales representatives and higher productivity per rep boosted performance. Operating income climbed 42.4% to a record $3.6 million, with operating margin improving to 19.2% of net revenue, while net income increased 40.3% to a record $2.8 million, or $0.32 per diluted share, marking the company’s thirteenth consecutive quarter of year-over-year revenue and net income growth.

Gross profit grew to $14.8 million, or 78.4% of net revenue, reflecting higher overall revenue and improved net revenue per device, while SG&A expenses rose 10% to $10.8 million, mainly due to larger sales headcount and higher compensation. Non-homecare revenue totaled $1.6 million, with growth in homecare distributor sales partly offset by declines in hospital and other revenue, indicating continued concentration in the core homecare market.

Electromed ended December 31, 2025, with $13.8 million in cash, $36.2 million in working capital, $45.4 million in total shareholders’ equity, and no debt, despite a $1.5 million cash decline over six months largely driven by $3.8 million of share repurchases. Management highlighted the success of its “Triple Down on Bronchiectasis” marketing campaign in raising physician and patient awareness among an estimated 800,000 diagnosed bronchiectasis patients who may benefit from SmartVest®, underscoring both the growth runway in its niche and a strategic focus on balancing reinvestment with shareholder returns.

The company’s record profitability and sustained multi-year growth streak reinforce its position as a niche leader in airway clearance technology and suggest effective execution of its direct homecare strategy. For investors and other stakeholders, the combination of double-digit revenue gains, expanding margins, ongoing buybacks, and a debt-free balance sheet points to a business generating robust cash flows while pursuing targeted commercial expansion in a specialized respiratory market.

The most recent analyst rating on (ELMD) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Electromed stock, see the ELMD Stock Forecast page.

Spark’s Take on ELMD Stock

According to Spark, TipRanks’ AI Analyst, ELMD is a Outperform.

The score is driven primarily by strong financial quality (high/expanding margins, improving ROE, and very low leverage) and a positive earnings update with ongoing execution initiatives and a buyback. Technicals are supportive with price above key moving averages, while valuation (P/E ~31 and no dividend yield provided) is the main constraint.

To see Spark’s full report on ELMD stock, click here.

More about Electromed

Electromed, Inc. is a U.S.-based medical device company that manufactures, markets, and sells airway clearance therapy products, including its flagship SmartVest Airway Clearance System, for patients with compromised pulmonary function. Headquartered in New Prague, Minnesota, and founded in 1992, the company is focused on serving chronic respiratory conditions such as bronchiectasis through direct homecare, distributor, and hospital channels.

The company has built its business around innovative airway clearance technologies and a growing direct salesforce targeting the sizeable diagnosed bronchiectasis population, particularly in the homecare market. Electromed emphasizes profitable growth, shareholder returns through stock repurchases, and maintaining a debt-free balance sheet with strong working capital to support ongoing commercial expansion.

Average Trading Volume: 52,325

Technical Sentiment Signal: Buy

Current Market Cap: $242.8M

See more data about ELMD stock on TipRanks’ Stock Analysis page.